Insmed enrolls adults in brensocatib phase 3 trial in bronchiectasis
Insmed Incorporated said that it has wrapped up enrollment of adult patients in the ASPEN phase 3 clinical trial of brensocatib in bronchiectasis. According to the New Jersey-based biopharma company, ASPEN is a global randomized, double-blind, placebo-controlled study that aims to examine the safety, efficacy, as well as tolerability of brensocatib in patients aged between […]